Grifols reported a 28.7% increase in net profit to €227 million for the first half of 2026. Revenues rose 2.6% at constant currency to €3.57 billion. The Biopharma division grew 5.4% behind strong demand for immunoglobulins. Free cash flow reached a positive €91 million, marking a significant turnaround for the company.
The company successfully refinanced all debt maturing in 2027 to strengthen its balance sheet. This move included an upsized term loan and an expanded credit facility. Grifols now faces no significant debt maturities until the fourth quarter of 2028. Management confirmed its full-year 2026 financial guidance following these results.